Ocular Therapeutix, Inc. OCUL
9.65
(0.17)
(1.73%)
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 0.0×
Follow OCUL
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(81.83%) | (54.85%) | (68.55%) | (72.99%) | |
| (55.41%) | (42.01%) | (51.03%) | (53.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(70.40%) | (35.41%) | (42.93%) | (49.04%) | |
Average Days of Receivables |
201.32 | 215.34 | 170.77 | 212.19 | |
Free Cash Flow per Share |
(1.08) | (1.16) | (1.07) | (1.13) | |
Free Cash Flow |
(199.31) | (216.76) | (240.81) | (255.10) | |
Capital Expenditures |
(9.24) | (11.88) | (14.61) | (16.86) | |
Piotroski F-Score |
1.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(28.22%) | (14.01%) | (17.13%) | (20.00%) | |
Accounts Receivable Turnover |
1.83 | 1.65 | 2.10 | 1.72 | |
Accounts Payable Turnover |
1.21 | 1.58 | 1.05 | 1.04 | |
Inventory Turnover |
2.11 | 1.99 | 1.90 | 1.95 | |
Average Days of Payables |
367.94 | 230.64 | 441.12 | 380.67 | |
Days of Inventory on Hand |
205.01 | 197.88 | 205.39 | 208.18 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
335.73% | 379.39% | 423.64% | 429.38% | |
Selling, General and Administrative Expense of Revenue |
202.78% | 227.71% | 239.03% | 260.78% | |
Share Based Compensation of Revenue |
69.95% | 83.12% | 92.84% | 102.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.76 | 0.77 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.24 | 0.22 | 0.25 | 0.28 | |
Capex/Depreciation |
(2.30) | (2.75) | (3.16) | (3.09) | |
Revenue per Share |
0.30 | 0.28 | 0.23 | 0.23 | |
Operating CF per Share |
(1.03) | (1.09) | (1.01) | (1.06) | |
Capex per Share |
(0.05) | (0.06) | (0.07) | (0.07) | |
Capex to Sales |
0.17 | 0.23 | 0.28 | 0.32 | |
Net Profit Margin |
(447.57%) | (511.90%) | (558.24%) | (579.10%) |
Columns are period end dates